Status:
TERMINATED
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
Lead Sponsor:
Fovea Pharmaceuticals SA
Conditions:
Macular Edema
Central Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.
Detailed Description
Occlusive retinal vascular disease is not uncommon. Central retinal vein occlusion (CRVO) is the second most common vision-impairing vascular disorder of the retina following diabetic retinopathy. Sev...
Eligibility Criteria
Inclusion
- Recent onset (\< 6 months), non-ischemic CRVO (defined as association of documented retinal hemorrhage in all 4 quadrants of the retina with dilated veins) in patients who have not received treatment for their condition (e.g., no periocular depot or intraocular treatment \[including corticosteroid and anti-VEGF\], systemic corticosteroids or laser nor hemodilution).
- Retinal thickness measured by Stratus OCT \> 250µm in the central subfield of study eye at baseline.
- BCVA score (measured by the ETDRS chart between 5 letters (20/800 Snellen equivalent) and 65 letters (20/50) in the study eye at baseline.
- Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs.
- Females of childbearing potential using adequate birth control at Day 0 until study completion.
- Patient able (in the opinion of the investigator) and willing to return for all scheduled visits and assessments.
- Ability to read, understand and willingness to provide informed consent.
Exclusion
- Rubeosis iridis or neovascular glaucoma at baseline.
- Preretinal neovascularisation at baseline.
- Ischemic CRVO, defined by more than 10 disc area of non-perfusion on fluorescein angiography at baseline.
- Any grade of diabetic retinopathy.
- Other eye condition that could contribute to macular edema or cause retinal vascular changes (including vitreomacular traction, uveitis and inflammatory disease, etc).
- Patients who have received treatment for their condition (e.g., no periocular depot or intraocular treatment \[including corticosteroid and anti-VEGF\], systemic corticosteroids or laser nor hemodilution).
- Ocular surgery (including cataract extraction, scleral buckle, etc.) and/or YAG capsulotomy within 3 months preceding treatment date or anticipated within the 3 months following treatment administration.
- Poorly controlled ocular hypertension and/or glaucoma (IOP greater than 25 mmHg despite maximal therapy).
- History of pars plana vitrectomy.
- Aphakia or anterior chamber intraocular lens.
- Presence of visible sclera thinning or ectasia.
- Presence of substantial cataract or other media opacity that, in the opinion of the investigator, is likely to interfere with visualization of the fundus or completion of study measurements.
- Any active ocular or peri-ocular infection (including conjunctivitis, chalazion or significant blepharitis).
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00969293
Start Date
September 1 2009
End Date
March 1 2012
Last Update
January 10 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Amiens, Centre Saint-Victor
Amiens, France, 80054
2
Centre Intercommunal de Creteil
Créteil, France, 94010
3
CHU de Dijon, Hôpital Général
Dijon, France, 21000
4
Clinique Monticelli
Marseille, France, 13008